Long non-coding RNA and tumor hypoxia: new players ushered toward an old arena

Journal of Biomedical Science

Review

Hsing-Jien Kung¹  Jing-Wen Shih² 

[1] Ph.D. Program for Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, 110, Taipei, Taiwan;Research Center of Cancer Translational Medicine, Taipei Medical University, 110, Taipei, Taiwan;Department of Biochemistry and Molecular Medicine, Comprehensive Cancer Center, University of California at Davis, 95817, Sacramento, CA, USA;Institute of Molecular and Genomic Medicine, National Health Research Institutes, 350, Zhunan, Miaoli County, Taiwan;Ph.D. Program for Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, 110, Taipei, Taiwan;Research Center of Cancer Translational Medicine, Taipei Medical University, 110, Taipei, Taiwan;Ph.D. Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University, 110, Taipei, Taiwan;

关键词: Hypoxia;    HIF-1α;    Long non-coding RNA;    lncRNA;    Cancer;    Hypoxia-responsive lncRNAs;    HRL;    Metastasis;   

DOI  :  10.1186/s12929-017-0358-4

 received in 2017-06-02, accepted in 2017-07-25,  发布年份 2017

来源: Springer

【 摘 要 】

Hypoxia is a classic feature of the tumor microenvironment with a profound impact on cancer progression and therapeutic response. Activation of complex hypoxia pathways orchestrated by the transcription factor HIF (hypoxia-inducible factor) contributes to aggressive phenotypes and metastasis in numerous cancers. Over the past few decades, exponentially growing research indicated the importance of the non-coding genome in hypoxic tumor regions. Recently, key roles of long non coding RNAs (lncRNAs) in hypoxia-driven cancer progression have begun to emerge. These hypoxia-responsive lncRNAs (HRLs) play pivotal roles in regulating hypoxic gene expression at chromatic, transcriptional, and post-transcriptional levels by acting as effectors of the indirect response to HIF or direct modulators of the HIF-transcriptional cascade. Notably, the aberrant expression of HRLs significantly correlates with poor outcomes in cancer patients, showing promise for future utility as a tumor marker or therapeutic target. Here we address the latest advances made toward understanding the functional relevance of HRLs, the involvement of these transcripts in hypoxia response and the underlying action mechanisms, highlighting their specific roles in HIF-1 signaling regulation and hypoxia-associated malignant transformation.

【 授权许可】

CC BY   
© The Author(s). 2017